Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma
Metastatic melanoma (MM) has a poor prognosis and is attributed to late diagnoses only when metastases has already occurred. Thus, early diagnosis is crucial to improve its overall treatment efficacy. The standard diagnostic tools for MM are incisional biopsies and/or fine needle aspiration biopsies, while standard treatments involve surgery, chemotherapy, or irradiation therapy. The combination of photodynamic diagnosis (PDD) and therapy (PDT) utilizes a photosensitizer (PS) that, when excited by light of a low wavelength, can be used for fluorescent non-destructive diagnosis. However, when the same PS is activated at a higher wavelength of light, it can be cytotoxic and induce tumor destruction. This paper focuses on PS drugs that have been used for PDD as well as PDT treatment of MM. Furthermore, it emphasizes the need for continued investigation into enhanced PS delivery via active biomarkers and passive nanoparticle systems. This should improve PS drug absorption in MM cells and increase effectiveness of combinative photodynamic methods for the enhanced diagnosis and treatment of MM can become a reality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 24(2019), 17 vom: 29. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Naidoo, Channay [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.01.2020 Date Revised 04.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules24173153 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30079939X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30079939X | ||
| 003 | DE-627 | ||
| 005 | 20231225103312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules24173153 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM30079939X | ||
| 035 | |a (NLM)31470637 | ||
| 035 | |a (PII)E3153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Naidoo, Channay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Metastatic melanoma (MM) has a poor prognosis and is attributed to late diagnoses only when metastases has already occurred. Thus, early diagnosis is crucial to improve its overall treatment efficacy. The standard diagnostic tools for MM are incisional biopsies and/or fine needle aspiration biopsies, while standard treatments involve surgery, chemotherapy, or irradiation therapy. The combination of photodynamic diagnosis (PDD) and therapy (PDT) utilizes a photosensitizer (PS) that, when excited by light of a low wavelength, can be used for fluorescent non-destructive diagnosis. However, when the same PS is activated at a higher wavelength of light, it can be cytotoxic and induce tumor destruction. This paper focuses on PS drugs that have been used for PDD as well as PDT treatment of MM. Furthermore, it emphasizes the need for continued investigation into enhanced PS delivery via active biomarkers and passive nanoparticle systems. This should improve PS drug absorption in MM cells and increase effectiveness of combinative photodynamic methods for the enhanced diagnosis and treatment of MM can become a reality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 5-Aminolevulinic acid (5-ALA) | |
| 650 | 4 | |a hypericin | |
| 650 | 4 | |a metastatic melanoma (MM) | |
| 650 | 4 | |a nanoparticles (NP) | |
| 650 | 4 | |a photodynamic diagnosis (PDD) | |
| 650 | 4 | |a photodynamic therapy (PDT) | |
| 650 | 4 | |a photosensitizer (PS) | |
| 650 | 4 | |a phthalocyanines | |
| 650 | 7 | |a Anthracenes |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Isoindoles |2 NLM | |
| 650 | 7 | |a Photosensitizing Agents |2 NLM | |
| 650 | 7 | |a Perylene |2 NLM | |
| 650 | 7 | |a 5QD5427UN7 |2 NLM | |
| 650 | 7 | |a hypericin |2 NLM | |
| 650 | 7 | |a 7V2F1075HD |2 NLM | |
| 650 | 7 | |a Aminolevulinic Acid |2 NLM | |
| 650 | 7 | |a 88755TAZ87 |2 NLM | |
| 650 | 7 | |a phthalocyanine |2 NLM | |
| 650 | 7 | |a V5PUF4VLGY |2 NLM | |
| 700 | 1 | |a Kruger, Cherie Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Abrahamse, Heidi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 24(2019), 17 vom: 29. Aug. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2019 |g number:17 |g day:29 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules24173153 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2019 |e 17 |b 29 |c 08 | ||